Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11894028 | 0.92 | CA12 (0.47) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL11894185 | 0.92 | CA12 (0.44) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL11894237 | 0.92 | CA12 (0.44) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL20527595 | 0.91 | CA12 (0.44) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL20527532 | 0.82 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL20527611 | 0.82 | CA12 (0.48) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL667939 | 0.82 | CA12 (0.50) | CA12CA1CA9CA2ALDH1A1 | |
| SCHEMBL1713412 | 0.80 | CA12 (0.40) | CA12CA1CA9CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11894281 | 0.80 | CA12 (0.48) | CA12CA1CA9CA2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11894016 | 0.80 | CA12 (0.48) | CA12CA1CA9CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030163000-A1 | Halogen exchange reactions and catalysts therefor | CHORDIP LTD. (GB) | 2003-08-28 | — | — | US | disclosed |
| EP-1288196-A1 | Process for the preparation of organo guanidinium salts | Chordip Ltd. (GB) | 2003-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030163000-A1 | Halogen exchange reactions and catalysts therefor | WEE2, WEE1, SLC39A11 | CA12 1147/4885CA1 1391/4885CA9 2034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.